MEK inhbitor drug approval

FOCUS on New Drug Approvals. Yesterday the FDA approved SpringWorks Therapeutics‘ Mirdametinib (PD-325901) for the treatment of patients with neurofibromatosis type 1 with symptomatic plexiform neurofibromas in adults and children. Mirdametinib is a non-ATP-competitive MEK inhibitor first developed by Parke-Davis Pharmaceuticals.

Focus Biomolecules can supply Mirdametinib (PD-325901) for research applications.